Etoposide-Carboplatin Alone or With Endostar for Extensive Disease Small Cell Lung Cancer (ED-SCLC)
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
Background:
The effect of existing treatment modalities of extensive disease small-cell lung cancer
(ED-SCLC) is unsatisfactory. Progress of new strategies including more efficient therapy is
wanted. Endostar® (Rh-endostatin Injection) may have anti-tumor activity by against vascular
endothelial growth factor for initial treatment. This study was designed to evaluate the
safety and efficacy of Endostar® combined with etoposide-carboplatin (EC) chemotherapy in
patients with ED-SCLC seeking for more effective treatment.